Kymera Therapeutics, Inc. (KYMR)
NASDAQ: KYMR · Real-Time Price · USD
46.56
+0.15 (0.32%)
At close: Oct 21, 2024, 4:00 PM
46.97
+0.41 (0.88%)
After-hours: Oct 21, 2024, 4:07 PM EDT
Kymera Therapeutics Revenue
Kymera Therapeutics had revenue of $25.65M in the quarter ending June 30, 2024, with 55.33% growth. This brings the company's revenue in the last twelve months to $88.55M, up 71.38% year-over-year. In the year 2023, Kymera Therapeutics had annual revenue of $78.59M with 67.84% growth.
Revenue (ttm)
$88.55M
Revenue Growth
+71.38%
P/S Ratio
34.28
Revenue / Employee
$473,529
Employees
187
Market Cap
2.97B
Revenue Chart
Revenue History
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
BrightSpring Health Services | 9.94B |
Bausch Health Companies | 9.20B |
Ardent Health Partners | 5.63B |
Astrana Health | 1.59B |
LivaNova | 1.21B |
PTC Therapeutics | 900.45M |
Protagonist Therapeutics | 319.12M |
Iovance Biotherapeutics | 32.77M |
KYMR News
- 12 days ago - Kymera Therapeutics Announces FDA Clearance of Investigational New Drug Application for KT-621, a First-in-Class, Oral STAT6 Degrader - GlobeNewsWire
- 15 days ago - Kymera's Protein Degradation Technology: A Promising Bet For Long-Term Biotech Investors - Seeking Alpha
- 26 days ago - Kymera Therapeutics Presents Preclinical Data for KT-621, a Potent, Selective, First-In-Class, Oral STAT6 Degrader at the EADV Congress - GlobeNewsWire
- 7 weeks ago - Kymera Therapeutics to Participate in Upcoming September Investor Conferences - GlobeNewsWire
- 2 months ago - Kymera Therapeutics Announces Closing of Upsized $225 Million Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares - GlobeNewsWire
- 2 months ago - Kymera Therapeutics Announces Pricing of $225 Million Public Offering - GlobeNewsWire
- 2 months ago - Kymera Therapeutics Announces Proposed Public Offering - GlobeNewsWire
- 2 months ago - Kymera Therapeutics, Inc. (KYMR) Q2 2024 Earnings Call Transcript - Seeking Alpha